Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection

Antibodies against HLA antigens cause refractory allograft rejection with vasculopathy in some patients. A non-HLA, anogiotensin II type 1 [AT(sub 1)] -receptor-mediated pathway might contribute to refractory vascular rejection, and affected patients might benefit from removal of [AT(sub 1)] -receptor antibodies or from pharmocologic blockade of [AT(sub 1)] receptors.